Skip to main content
Publish date:

Vertex Soars on Hepatitis Results

The company's drug seems to show some promise.


(VRTX) - Get Vertex Pharmaceuticals Incorporated Report

surged 20% Friday after the company reported positive results from a study of its hepatitis C drug.

The company said data suggest wild-type hepatitis C virus and resistant variants were suppressed in patients when pegylated interferon was added to telaprevir (VX-950), Vertex's investigational hepatitis C virus protease inhibitor, in a Phase 1b clinical study.

TheStreet Recommends

The Cambridge, Mass., biotech said 24 of 26 patients who received telaprevir (VX-950) in two early-stage clinical trials had undetectable HCV RNA after receiving follow-on combination therapy with peg-IFN and ribavirin (RBV) through 24 weeks of treatment, a therapeutic regimen following the conclusion of the clinical trials.

Clinical investigators will also report that some of these patients have stopped therapy, and that a proportion of them continued to have undetectable HCV RNA after stopping therapy, Vertex said.

Share rose $6.61 to $41.18.